Recent articles

They shared new developments and applauded the speed of scientific advancements. At this year’s Strategic Research Session, the tone was dynamic as Breakthrough T1D’s internal team of scientists, leading type 1 diabetes (T1D) researchers, innovative strategic advisors and volunteers from the T1D community came together to chart the direction of Breakthrough T1D research for the […]

Immune therapy has transformed cancer care. In some cases, cancer is effectively cured in people with stage 4 disease. But it has a catch: In about one percent of people treated with immune therapy, their immune system goes haywire, and it attacks the beta cells in the pancreas, leaving them with type 1 diabetes (T1D) […]

 Breakthrough T1D funds type 1 diabetes (T1D) clinical trials that are critical to bringing new devices and treatments to people with this disease. Currently, there are more than 70 Breakthrough T1D-funded clinical trials, to both prevent and treat this disease and its complications. We hope that, ultimately, these trials will lead to a cure for […]

As many of you know, UnitedHealthcare (UHC) has limited insulin pump choice for children and adults through a new policy called a preferred pump agreement. Breakthrough T1D believes that consumer choice is essential for the T1D community, and that an insurance company should never stand between a patient and doctor. To that end, we have […]

In Nature Metabolism, Breakthrough T1D-funded researchers—including the lead author, Ercument Dirice, Ph.D., and senior author, Rohit Kulkarni, M.D., Ph.D.—found an unidentified piece of information: By enhancing beta cell mass secondary to a robust beta cell proliferation early in life, they could protect mice from developing type 1 diabetes (T1D). I’ll say that again: By enhancing […]

Press releases

Read the latest press releases and statements from Breakthrough T1D.

Get the latest in T1D news updates

Sign up for Insider News to receive breaking news updates from Breakthrough T1D.

  • This field is for validation purposes and should be left unchanged.